GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

NCT00715624 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Lixisenatide (AVE0010)
DRUG: Placebo
DRUG: Basal Insulin
DRUG: Metformin
DEVICE: Pen auto-injector

Sponsor

Sanofi